Sonnet BioTherapeutics (SONN) announced the presentation of a compilation of data at the 2025 American Association for Cancer Research, AACR, IO Conference. As part of the conference, Dr. Sant Chawla, Principal Investigator at the Sarcoma Oncology Center in Santa Monica, California, presented a poster entitled, “Combination immunotherapy with an albumin-binding interleukin-12 fusion protein that extends cytokine half-life, targets the tumor microenvironment, and enhances therapeutic efficacy.” This is the first time the overall strategy of Sonnet’s Fully Human Albumin Binding platform has been compiled with existing data and presented in a poster. The presented poster is now available on the Publications page of the Company’s website.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SONN:
- Sonnet BioTherapeutics Advances Antibody Drug Conjugate Platform
- Sonnet announces ADC platform available for drug discovery partnerships
- Sonnet Biotherapeutics Reports Increased Revenue and Strategic Developments
- Sonnet BioTherapeutics appoints McAndrew as Chief Business Officer
- Sonnet BioTherapeutics reports Q1 EPS ($1.56) vs ($2.46) last year